Beta Bionics, INC 8-K filings

Beta Bionics reported a 38% year-over-year increase in second quarter 2026 net sales to $32.0 million, driven by strong performance in the Pharmacy Benefit Plan channel, while net loss widened to $23.4 million.

Beta Bionics announces updated timeline for its Mint patch pump, now expecting full commercialization by Q2 2027, pending FDA clearance.

Beta Bionics reported a 57% year-over-year increase in first quarter 2026 net sales to $27.6 million, driven by strong performance in the Pharmacy Benefit Plan channel, and raised its full-year revenue guidance.

Beta Bionics, Inc. received a U.S. Food and Drug Administration warning letter citing deficiencies in its quality management system and reporting, though it does not expect a material impact on product commercialization.

Beta Bionics announced preliminary, unaudited fourth quarter 2025 topline financial results showing significant growth in net sales and customer base.

Beta Bionics reported strong third-quarter 2025 financial results, including a 63% increase in net sales, and subsequently raised its full-year 2025 guidance.

Beta Bionics, Inc. announced robust second-quarter 2025 financial results, including a 54% increase in net sales, and subsequently raised its full-year 2025 guidance.

Beta Bionics, Inc. announced compelling real-world data for its iLet Bionic Pancreas, showing significant improvements in glycemic control and hypoglycemia management across diverse user groups, including those transitioning from other insulin therapies.

Beta Bionics announced a 36% increase in first quarter revenue and raised its full year 2025 revenue guidance.

Beta Bionics has appointed Gerard Michel as a Class III director, effective March 26, 2025, with a term expiring at the 2028 annual meeting of stockholders.

Beta Bionics announces significant revenue growth for 2024 and provides encouraging financial guidance for 2025, driven by increased adoption of its iLet Bionic Pancreas.

Beta Bionics successfully closed its initial public offering and a concurrent private placement, raising a total of $229.1 million in gross proceeds.